Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug The objective of this study is to explore the efficacy of crizotinib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the crizot...

• Country None
• organs None
• Specialty None

Open-label, randomized, multicenter, international, parallel exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of stage II-IIIA PAM 50 defined Luminal breast cancer, in postmenopausal women To evaluate the ability of each treatment strategy to provide RCB 0-I pathological tumor response at surgery (local assessment) in luminal A N+ and luminal B patients subgroup.

• Country None
• organs None
• Specialty None

Abiraterone acetate in Molecular Apocrine breast cancer To estimate antitumor activity of abiraterone acetate, as measured by the 6 months clinical benefit rate (CBR) in molecular apocrine HER2-negative locally advanced or metastatic breast cancer.

• Country None
• organs None
• Specialty None

Secured access to pembrolizumab for adult patients with selected rare cancer types The primary objective of the trial is to evaluate the response to pembrolizumab monotherapy in cohorts of patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral ...

• Country None
• organs None
• Specialty None

Secured access to nivolumab for adult patients with selected rare cancer types The primary objective of the trial is to evaluate the efficacy response to nivolumab monotherapy in cohorts of patients with unresectable locally advanced or metastatic, non-clear cell RCC, rare head ...

• Country None
• organs None
• Specialty None

Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations To explore the efficacy of vemurafenib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the vemurafenib target gene, per cohort.

• Country None
• organs None
• Specialty None

A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas The principal objective of the trial is to investigate the antitumor activity of regorafenib in terms of progression Free Survival (PFS) according to modified RECIST (RECIST 1.1) after central radiolo...

• Country None
• organs None
• Specialty None

Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial Traitement adjuvant systémique du cancer du sein avec récepteurs aux œstrogènes-positifs et HER2-négatif de la femme de plus de 70 ans en fonction du grade génomique (GG) : chimiothérapie et hormonothérapie versus hormonothérapie seule. Etude multicentrique de phase III des groupes UNICANCER GERICO et UCBG _ Evaluation du bénéfice de la chimiothérapie adjuvante sur la survie globale (SG) dans le sous-groupe de patientes âgées présentant un risque de rechute élevé selon le Grade Génomique (GG).

• Country None
• organs None
• Specialty None

AFU-GETUG20 Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in p...

• Country None
• organs None
• Specialty None

A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer To assess the efficacy of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in terms of overall survival (OS) and progression-free surv...

• Country None
• organs None
• Specialty None